Neuroone Competitors

Stocks . USA . 
Stock . Neuroone Medical Technologies
NMTC Stock  USD 1.05  0.01  0.96%   
Neuroone Medical Tec competes with BioSig Technologies,, Biomerica, Beyond Air, Movano, and SANUWAVE Health; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing Neuroone Medical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Neuroone Medical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Neuroone Medical Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Neuroone Medical competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neuroone Medical's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.051.057.56
Details
Intrinsic
Valuation
LowRealHigh
0.040.807.31
Details

Neuroone Medical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Neuroone Medical and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Neuroone and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Neuroone Medical Tec does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
NPCE
+ 0.91
LNSR
XAIR
+ 0.66
BSGM
NPCE
+ 0.61
MOVE
LNSR
+ 0.53
BSGM
LNSR
+ 0.48
MOVE
DYNT
+ 0.47
XAIR
  
High negative correlations   
DYNT
- 0.73
SNWV
XAIR
- 0.73
NMRD
NPCE
- 0.72
DYNT
LNSR
- 0.69
DYNT
DYNT
- 0.63
MOVE
DYNT
- 0.53
NMRD

Risk-Adjusted Indicators

There is a big difference between Neuroone Stock performing well and Neuroone Medical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Neuroone Medical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
BSGM  9.91  2.94  0.29  3.67  9.22 
(12.22)
 34.00 
(16.94)
 78.79 
NMRD  4.82  0.33  0.05  1.72  5.23 
(6.03)
 14.29 
(9.72)
 35.66 
BMRA  6.86  1.68  0.26 (1.71) 5.19 
(11.10)
 17.86 
(8.57)
 41.32 
XAIR  5.55  0.65  0.09 (1.60) 5.99 
(6.75)
 10.81 
(9.09)
 36.74 
MOVE  5.00  0.48  0.08  0.43  5.86 
(6.19)
 11.06 
(9.04)
 61.96 
SNWV  4.40  1.19  0.22 (50.73) 4.06 
(5.19)
 9.54 
(7.89)
 31.30 
DYNT  5.03 (0.72) 0.00 (1.72) 0.00 
 0.00 
 7.50 
(12.77)
 69.48 
LNSR  3.37  0.70  0.21  1.68  2.84 
(4.03)
 8.92 
(4.97)
 22.21 
NPCE  3.55  1.04  0.28  1.41  3.02 
(4.32)
 9.73 
(6.20)
 35.79 
OSA  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
All Fundamental Data

Neuroone Medical Competitive Analysis

The better you understand Neuroone Medical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Neuroone Medical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Neuroone Medical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NMTC BSGM NMRD BMRA XAIR MOVE SNWV DYNT LNSR NPCE
 0.96 
 1.05 
Neuroone
 1.69 
 1.16 
BioSig
 1.06 
 0.93 
Nemaura
 9.86 
 0.64 
Biomerica
 13.51 
 0.42 
Beyond
 1.92 
 5.63 
Movano
 0.61 
 26.50 
SANUWAVE
 0.00 
 0.20 
Dynatronics
 2.92 
 8.32 
LENSAR
 0.50 
 11.97 
Neuropace
Market Volatility
(90 Days Market Risk)
Abnormally volatile
Out of control
Very steady
Extremely Dangerous
Abnormally volatile
Moderately volatile
Somewhat reliable
Very steady
Slightly risky
Slightly risky
Market Performance
(90 Days Performance)
Insignificant
OK
Very Weak
OK
Insignificant
Modest
Solid
Very Weak
Good
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Below Average
Dangerous
Quite High
Very High
Low
Low
Dangerous
Low
Above Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Sell
Buy
Buy
Not Available
Not Available
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Strong Sell
Strong Sell
Current Ratio
13.42
1.22
0.99
5.22
8.41
6.78
0.1
1.93
3.14
9.86
Net Asset
5.37 M
1.8 M
14.56 M
9.25 M
56.96 M
9.42 M
23.03 M
30.06 M
69.58 M
107.65 M
Profit Margin
N/A
N/A
N/A
-1.12
N/A
N/A
-0.75
-0.13
-0.34
-0.37
EBITDA
(11.84 M)
(28.15 M)
(8.17 M)
(5.99 M)
(59.03 M)
(29.12 M)
(31.95 M)
(3.5 M)
(8.71 M)
(22.83 M)
Operating Margin
-3.38
-227.43
N/A
-0.76
-19.88
-31.99
-0.54
-0.0747
-0.092
-0.2
Current Valuation
31.18 M
6.43 M
22.58 M
9.99 M
14.96 M
26.18 M
49.31 M
15.41 M
80.45 M
373.95 M
Price To Book
39.4
36.58
122.56
2.29
1.07
3.64
N/A
0.25
4.25
36.37
Retained Earnings
(75 M)
(245.01 M)
(51.88 M)
(48.2 M)
(239.7 M)
(124.38 M)
(96.98 M)
(25.48 M)
(111.89 M)
(503.81 M)
Current Asset
94.49 M
984.54 K
9.55 M
4.77 M
N/A
138.64 M
1.04 M
9.91 M
N/A
N/A
Beta
0.91
0.84
0.046
-1.14
-0.18
0.19
0.67
0.24
0.59
1.8
Number Of Employees
16
4
36
64
107
30
40
154
130
184
Shares Outstanding
30.84 M
14.12 M
28.9 M
16.82 M
72.19 M
6.6 M
548.74 M
5.31 M
11.61 M
29.85 M
Cash Flow From Operations
(11.01 M)
(17.31 M)
(8.45 M)
(5.36 M)
(56.01 M)
(26.18 M)
(12.72 M)
372 K
(9.66 M)
(19.7 M)
Total Debt
260.16 K
452 K
20.03 M
785 K
17.84 M
217 K
875 K
5.65 M
2.31 M
72.39 M
Return On Equity
-3.49
-59.77
-7.24
-0.76
-2.19
-1.81
N/A
-0.26
-0.38
-2.15
Z Score
N/A
N/A
-7.48
N/A
N/A
N/A
7.3
N/A
N/A
N/A
Return On Asset
-1.43
-4.48
-0.49
-0.39
-0.63
-0.89
-0.26
-0.0831
-0.0938
-0.15
Number Of Shares Shorted
70.3 K
461.7 K
52.57 K
364.05 K
1.16 M
28.39 K
N/A
15.91 K
66.61 K
263.29 K
Book Value Per Share
0.11
-0.39
-0.55
0.32
0.55
2.54
-0.06
1.41
1.96
0.33
Current Liabilities
18.26 M
2.47 M
658.01 K
445 K
N/A
40.62 M
1.39 M
4.3 M
N/A
N/A
Total Asset
5.37 M
1.8 M
14.56 M
9.25 M
56.96 M
9.42 M
23.03 M
30.06 M
69.58 M
107.65 M
Debt To Equity
0.021
0.45
N/A
0.16
0.046
0.025
N/A
0.18
0.068
1.08
Short Ratio
0.6
0.95
0.3
2.28
1.62
3.76
N/A
0.29
1.32
3.75
Target Price
3.15
6.0
3.5
13.0
2.5
30.0
0.34
4.0
11.0
16.17
Shares Owned By Institutions
19.43
3.04
7.7
13.01
36.39
13.84
5.85
7.09
42.4
82.9
Market Capitalization
32.38 M
6.64 M
2.43 M
5.46 M
30.14 M
27.72 M
24.09 M
1.27 M
96.64 M
357.28 M
Price To Earning
-23.53
-3.73
-707.14
-25.64
N/A
39.53
-3.33
47.23
N/A
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
8.26
90.04
804.62
2.13
16.9
43.83
1.06
0.0543
1.98
4.67
Net Income
(12.32 M)
(28.69 M)
(14.14 M)
(5.98 M)
(60.24 M)
(29.28 M)
(30.94 M)
(4.97 M)
(14.38 M)
(32.96 M)
Earnings Per Share
-0.46
-0.86
-0.39
-0.37
-1.41
-5.8
-0.051
-1.21
-1.46
-0.98
Shares Owned By Insiders
16.01
17.59
48.3
7.22
16.35
17.33
7.09
41.08
19.57
4.1
Revenue
3.45 M
18 K
77.04 K
5.42 M
1.16 M
N/A
4.06 M
40.61 M
42.16 M
65.42 M
Working Capital
2.42 M
(4.05 M)
(8.73 M)
5.53 M
32.37 M
2.62 M
(356 K)
4.48 M
34.81 M
76.49 M
Cash And Equivalents
10.18 M
887 K
14.75 M
6.08 M
72.77 M
21.3 M
1.48 M
550.11 K
25.2 M
92.41 M
Cash Per Share
0.63
0.02
0.61
0.45
2.43
0.65
N/A
0.03
2.29
3.72
Gross Profit
(4.6 M)
242 K
(1.48 M)
446 K
(1.4 M)
N/A
8.02 M
10.15 M
23.89 M
56.44 M
Day Typical Price
1.05
1.2
0.94
0.66
0.43
5.61
26.67
0.2
8.38
11.94
Accumulation Distribution
0.0826
0.0866
0.1
0.2
0.17
0.069
0.0258
0.0952
0.0633
0.0281
Market Facilitation Index
0.09
0.11
0.1
0.15
0.08
0.4
0.7
0.02
0.55
0.34
Daily Balance Of Power
0.1111
(0.18)
(0.10)
(0.47)
0.625
(0.28)
0.2286
N/A
(0.45)
0.1765
Period Momentum Indicator
0.01
(0.02)
(0.01)
(0.07)
0.05
(0.11)
0.16
N/A
(0.25)
0.06
Rate Of Daily Change
1.01
0.98
0.99
0.9
1.14
0.98
1.01
1.0
0.97
1.01
Day Median Price
1.05
1.21
0.95
0.68
0.43
5.6
26.75
0.2
8.41
11.92
Price Action Indicator
0.01
(0.07)
(0.03)
(0.07)
0.015
(0.03)
(0.17)
N/A
(0.22)
0.08
Coefficient Of Variation
1565.61
483.01
2006.49
861.1
1072.87
1662.44
484.93
(1,243)
621.5
495.67
Mean Deviation
4.75
9.91
4.82
6.86
5.55
5.0
4.4
5.03
3.37
3.55
Jensen Alpha
0.4099
2.94
0.3334
1.68
0.6485
0.4843
1.19
(0.72)
0.6961
1.04
Total Risk Alpha
0.2486
2.62
0.1731
1.32
0.4762
0.3049
1.05
(0.92)
0.5997
0.9324
Sortino Ratio
0.0718
0.2889
0.0534
0.2575
0.0902
0.0771
0.2247
N/A
0.2109
0.2819
Downside Variance
28.05
103.43
35.41
40.51
47.39
40.05
27.24
N/A
10.54
13.54
Standard Deviation
6.42
14.33
6.97
14.37
6.98
8.61
5.83
8.72
4.44
5.29
Kurtosis
0.7052
3.59
2.18
38.6
0.3571
16.55
1.06
15.76
2.14
9.63
Potential Upside
13.04
34.0
14.29
17.86
10.81
11.06
9.54
7.5
8.92
9.73
Treynor Ratio
(0.78)
3.67
1.72
(1.71)
(1.60)
0.4265
(50.73)
(1.72)
1.68
1.41
Maximum Drawdown
28.93
78.79
35.66
41.32
36.74
61.96
31.3
69.48
22.21
35.79
Variance
41.16
205.49
48.54
206.49
48.73
74.08
33.98
76.0
19.71
27.97
Market Risk Adjusted Performance
(0.77)
3.68
1.73
(1.70)
(1.59)
0.4365
(50.72)
(1.71)
1.69
1.42
Risk Adjusted Performance
0.0621
0.1825
0.0505
0.1065
0.0867
0.0593
0.1809
(0.06)
0.1426
0.1771
Skewness
0.7732
1.43
1.11
5.54
0.1986
2.58
0.5159
2.41
1.17
2.14
Semi Deviation
4.54
9.22
5.23
5.19
5.99
5.86
4.06
N/A
2.84
3.02
Information Ratio
0.0592
0.205
0.0456
0.1141
0.089
0.0567
0.2011
(0.08)
0.1542
0.1961
Value At Risk
(9.52)
(16.94)
(9.72)
(8.57)
(9.09)
(9.04)
(7.89)
(12.77)
(4.97)
(6.20)
Expected Short fall
(7.42)
(12.22)
(6.03)
(11.10)
(6.75)
(6.19)
(5.19)
N/A
(4.03)
(4.32)
Downside Deviation
5.3
10.17
5.95
6.36
6.88
6.33
5.22
N/A
3.25
3.68
Semi Variance
20.62
85.06
27.4
26.94
35.89
34.4
16.48
N/A
8.06
9.1

Neuroone Medical Competition Performance Charts

Five steps to successful analysis of Neuroone Medical Competition

Neuroone Medical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Neuroone Medical Tec in relation to its competition. Neuroone Medical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Neuroone Medical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Neuroone Medical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Neuroone Medical Tec, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Neuroone Medical position

In addition to having Neuroone Medical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Adviser Favorites Thematic Idea Now

Adviser Favorites
Adviser Favorites Theme
Financial advisors frequently recommend that individuals diversify their investment portfolios with a mix of different types of stocks. These can include blue-chip stocks, growth stocks, and dividend stocks. The Adviser Favorites theme has 14 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Adviser Favorites Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Neuroone Medical Tec offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neuroone Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neuroone Medical Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neuroone Medical Technologies Stock:
How To Invest In Neuroone
Details
Is Neuroone Stock a good investment?
Details
What is Neuroone Medical's Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out Neuroone Medical Correlation with its peers.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuroone Medical. If investors know Neuroone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuroone Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neuroone Medical Tec is measured differently than its book value, which is the value of Neuroone that is recorded on the company's balance sheet. Investors also form their own opinion of Neuroone Medical's value that differs from its market value or its book value, called intrinsic value, which is Neuroone Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuroone Medical's market value can be influenced by many factors that don't directly affect Neuroone Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Neuroone Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuroone Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuroone Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY